The two firms have entered a non-exclusive agreement to co-market their products and outsourcing services to customers, and will also collaborate on the development of new projects.
LibraGen has developed a platform that allows it to discover new enzymes from metabolic pathways that are not exploited by the industry at present. Synkem , which specialises in supplying active pharmaceutical ingredients (APIs), will contribute its expertise in process research and Good Manufacturing Practice (GMP) production.
"By entering this partnership, LibraGen will gain access to a wider number of customers" for its biocatalysts, said Renaud Nalin, LibraGen 's CEO.
